Bristol-Myers Squibb Co. (NYSE:BMY)
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
ottsboleego
(79.91)
Submitted: 4/2/2008 1:37:40 PM :
Start Price:
$17.76
BMY Score:
+86.13
will correct lack of products .
Recs
boomho603
(91.53)
Submitted: 4/2/2008 10:51:46 AM :
Start Price:
$17.82
BMY Score:
+86.03
Slow economy, pays dividend. buy and hold.
Recs
HighYield50
(30.81)
Submitted: 4/1/2008 7:30:13 PM :
Start Price:
$17.97
BMY Score:
+84.29
#28 yield in S & P 500 as of 04/01/08.
Recs
jim001x
(35.38)
Submitted: 3/23/2008 8:23:35 PM :
Start Price:
$17.33
BMY Score:
+88.18
At 21.46 BMY is trading close to its 52 week low with a 5.78% DY.
Last Morningstar fair value estimates were $26 and 23. S&P has a $26 target price.
BMY Was recommended by Chuck Carlson with Quadrix 1st of the year and gone down since like many others. i'll be getting paid to wait for it to come back and if it goes up $1 that's another 5%.
Fundamentally, has lowest P/S and highest 5 year EPS growth over
next 5 years among its peers.
Recs
jason25840
(60.83)
Submitted: 3/17/2008 3:44:56 PM :
Start Price:
$16.59
BMY Score:
+92.83
Pharmaceuticals are going to grow and bio-based and genomic based research will help make bristol myers pay off.
Recs
PapaSwine
(82.98)
Submitted: 3/17/2008 3:18:00 PM :
Start Price:
$16.60
BMY Score:
+91.90
Price target in the 40s. Nice pipeline of drugs. Segment undervalued
Recs
kahunacfa
(66.71)
Submitted: 2/29/2008 1:13:05 PM :
Start Price:
$18.36
BMY Score:
+77.98
In a Bear Market, Food and Drug stocks are usually a "safe Haven"
Although BMY at about $22.77 has a higer multiple of nearly 23 times earnings, I will pick the stock for CAPS. I might actually buy the stock will real money at $9 to $10 per share.
Kahuna,CFA
Recs
dtorres28
(74.69)
Submitted: 2/22/2008 5:37:44 PM :
Start Price:
$18.10
BMY Score:
+81.29
Baby boomers . . . need I say more?
Recs
mackfack
(90.85)
Submitted: 1/31/2008 4:14:57 PM :
Start Price:
$18.66
BMY Score:
+77.53
Kicked into the ground by pipeline issues and one-time charges. Great divvy and enough cash to rebuild.
Recs
bigsmooth
(70.21)
Submitted: 1/23/2008 3:43:32 PM :
Start Price:
$18.14
BMY Score:
+78.76
Seems too cheap at this price, especially with a good dividend. It should be in everyones' portfolio at this price.
Recs
PicoTrader
(< 20)
Submitted: 1/15/2008 1:20:21 PM :
Start Price:
$21.22
BMY Score:
+56.70
drug play so defensive in nature, great company with good fundamentals and one of the better positioned for growth in this sector; oh yes and dividends not bad!
Recs
Gervais001
(62.26)
Submitted: 1/12/2008 12:18:51 PM :
Start Price:
$21.55
BMY Score:
+56.00
Good company sitting at a deep discount.
Recs
ktcr
(< 20)
Submitted: 12/28/2007 4:34:12 PM :
Start Price:
$21.54
BMY Score:
+60.06
troubles behind it, new CEO, good dividend, biologic investments
Recs
newbie740
(< 20)
Submitted: 12/6/2007 4:22:14 PM :
Start Price:
$23.17
BMY Score:
+51.42
Restructuring to control costs and some important coming on line (from P3) bodes well as we move forward.
Recs
OmniGator
(67.69)
Submitted: 12/4/2007 3:54:40 PM :
Start Price:
$23.17
BMY Score:
+48.46
Most of the legal issues have been settled
Recs
TopDividendPayer
(99.48)
Submitted: 12/1/2007 5:44:51 AM :
Start Price:
$23.65
BMY Score:
+47.03
This CAPS account is tracking the 200 highest yielding S&P stocks.
Recs
Jorgedig
(27.87)
Submitted: 11/15/2007 11:22:01 PM :
Start Price:
$22.27
BMY Score:
+54.00
Ixempra got fast-track approval for taxane/anthracycline failed pts in the metastatic setting. Currently in trials for new breast indications and other tumor types, i.e. pancreatic, ovarian, non-small cell lung ca.
Recs
DownGraded
(64.27)
Submitted: 10/30/2007 5:20:37 PM :
Start Price:
$23.94
BMY Score:
+48.33
Bristol Meyers is an old stalwart. Although it has some ups and down, it weathers the storms and is continuing to grow while increasing dividends year over year.
Recs
balilight
(40.58)
Submitted: 10/29/2007 12:09:46 AM :
Start Price:
$23.74
BMY Score:
+49.46
Big pharma may not be sexy but the 3.5 Quarterly dividend yeild, good pavlix sales and seady performance is very attractive in these volital times.
Recs
jacobr57
(99.33)
Submitted: 10/16/2007 5:13:09 PM :
Start Price:
$23.67
BMY Score:
+50.49
Just got approval from the FDA to sell its new breast cancer drug ixempra
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 161 - 180 of 233 : « Previous 4 5 6 7 8 9 10 11 12 Next »